Drugs of Abuse Confirmation/Quantitation - Amphetamines (Amphetamine and Methamphetamine) - Meconium

0092310
copy
 

Copy Utility


emailprint
Example Reports
Negative
Positive
Ordering Recommendation

• Use for infant drug testing when only amphetamine-based stimulant exposure is of clinical interest or when quantity of meconium available for testing is very small (eg, <1 g).
• Preferred test is Drugs of Abuse Panel, Meconium - Screen with Reflex to Confirmation/Quantitation (0092516).

Mnemonic
CONFAMP M
Methodology

Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

Performed

Sun-Sat

Reported

1-4 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

All meconium (blackish material) excreted until milk/formula based stool (yellow-green) appears.

Specimen Preparation

Transport 0.5 g (equivalent to 1/2 inch cube) for each separate confirmation required. (Min: 0.13 g or 1/4 inch cube)

Storage/Transport Temperature

Room temperature.

Unacceptable Conditions
Remarks
Stability

Ambient: 1 week; Refrigerated: 3 months; Frozen: 1 year

Reference Interval
Interpretive Data

Drugs Covered: amphetamine, methamphetamine, methylenedioxymethamphetamine (MDMA-Ecstasy), methylenedioxyethylamphetamine (MDEA - Eve), and methylenedioxyamphetamine (MDA).
Positive cutoff: 20 ng/g

Meconium begins to form between the 12th and 16th week of gestation. Meconium drug testing can detect maternal drug use during the last 4 to 5 months of pregnancy. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drug use depends on the quantity and quality of the specimen tested as well as the pattern and frequency of drug(s) used by mother. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
Hotline History
N/A
CPT Codes

80324; 80359 (Alt code: G0480)

Are you an ARUP Client? Click here for your pricing.
Components
Component Test Code* Component Chart Name LOINC
0092310 Drug Confirmation, Amphetamines, Mec 26959-7
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Adderall
  • Amphetamine
  • Benzedrine
  • Carbex
  • Deprenyl
  • Desoxyephedrine
  • Desoxyn
  • Dexedrine
  • Dextroamphetamine
  • Ecstasy
  • Eldepryl
  • Emsam
  • Eve
  • Lisdexamfetamine
  • MDA
  • MDEA
  • MDMA
  • Methamphetamine
  • Methedrine
  • Paremyd
  • Selegiline
  • Vicks Inhaler
  • Vyvanse
  • XTC
  • Zelapor
Drugs of Abuse Confirmation/Quantitation - Amphetamines (Amphetamine and Methamphetamine) - Meconium